The global market for novel weight-loss drugs like Novo Nordisk A/S's Ozempic and Wegovy is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications.
An advisory panel to the FDA unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA twice rejected the implant.
Washington's revolving door kept spinning this week as the DEA's recently departed second-in-command returned for a new stint with the high-powered consulting firm where he previously advised Purdue Pharma and a drug distributor.
Republicans and Democrats fought it out over Medicare drug price negotiation Wednesday at a House hearing, with the former accusing the latter of setting up 'mafia-style' theft of property.
The Washington Post found more than two dozen websites that bypass doctors and pharmacies completely to sell semaglutide — the active ingredient in Ozempic and Wegovy — directly to consumers.